scholarly journals Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases

2015 ◽  
pp. 289
Author(s):  
Vincenzo Adamo ◽  
Giuseppina Rosaria Rita Ricciardi ◽  
Alessandro Russo ◽  
Tindara Franchina ◽  
Giuseppa Ferraro
Keyword(s):  
Breast Cancer ◽  
Brain Metastases ◽  
Cancer Patient ◽  
Breast Cancer Patient ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Heavily Pretreated ◽  
Positive Breast Cancer

Repeated courses of radiation treatment in an HER2‐positive breast cancer patient with diffuse brain metastases: A case report

2020 ◽  
Vol 26 (7) ◽  
pp. 1370-1371
Author(s):  
Sonia Silipigni ◽  
Edy Ippolito ◽  
Paolo Matteucci ◽  
Bianca Santo ◽  
Emma Gangemi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Case Report ◽  
Brain Metastases ◽  
Cancer Patient ◽  
Breast Cancer Patient ◽  
Radiation Treatment ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Diffuse Brain ◽  
Positive Breast Cancer

scholarly journals Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases

ESMO Open ◽  
2017 ◽  
Vol 2 (4) ◽  
pp. e000253 ◽  
Author(s):  
Giulia Siravegna ◽  
Elena Geuna ◽  
Benedetta Mussolin ◽  
Giovanni Crisafulli ◽  
Alice Bartolini ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cerebrospinal Fluid ◽  
Brain Metastases ◽  
Cancer Patient ◽  
Breast Cancer Patient ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

Retinal metastases treated with lapatinib (L) in a young HER2-positive breast cancer patient: Case report

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 12008-12008
Author(s):  
M. Sarti ◽  
O. Pagani ◽  
F. Bertoni ◽  
S. Longhi ◽  
C. Cafaro ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Case Report ◽  
Cancer Patient ◽  
Breast Cancer Patient ◽  
Patient Case ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer

2007 ◽  
Vol 85 (3) ◽  
pp. 311-317 ◽  
Author(s):  
Rupert Bartsch ◽  
Andrea Rottenfusser ◽  
Catharina Wenzel ◽  
Karin Dieckmann ◽  
Ursula Pluschnig ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Brain Metastases ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

scholarly journals Systemic Treatment Options for HER2-Positive Breast Cancer Patients with Brain Metastases beyond Trastuzumab: A Literature Review

Breast Care ◽  
2017 ◽  
Vol 12 (3) ◽  
pp. 168-171 ◽  
Author(s):  
Elena Laakmann ◽  
Volkmar Müller ◽  
Marcus Schmidt ◽  
Isabell Witzel
Keyword(s):  
Breast Cancer ◽  
Brain Metastases ◽  
Cancer Patients ◽  
Systemic Treatment ◽  
Treatment Options ◽  
Cytotoxic Agents ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

Background: The incidence of brain metastases (BM) in breast cancer patients has increased. Many retrospective analyses have shown that first-line treatment with trastuzumab prolongs survival in patients with HER2-positive BM. In contrast, the evidence for other therapies targeting HER2 for patients with BM is rare. Methods: The aim of this review is to update the reader about current systemic treatment options in patients with HER2-positive metastatic breast cancer with BM who had already received trastuzumab. A literature search was performed in the PubMed database in June 2016. 30 relevant reports concerning the efficacy of trastuzumab emtansine (T-DM1), lapatinib and its combination with other cytotoxic agents, pertuzumab and novel HER2-targeting substances were identified. Results: There is limited but promising evidence for the use of T-DM1 and pertuzumab in the treatment of BM. Up to now, most reported studies used lapatinib as treatment of HER2-positive breast cancer with BM, a treatment with only a modest effect and a high toxicity profile. The combination of lapatinib with cytotoxic agents seems to result in better response rates. Conclusion: Further prospective investigations are needed to investigate the efficacy of the established and novel HER2-targeting agents on BM in HER2-positive breast cancer patients.

Sign in / Sign up

Export Citation Format

Share Document